GlassScriptPhysician profile
Eugene H Jackson
NPI 1538165386
$4,017.23
in general payments reported to CMS, 2019-2025
35 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $590 · 2020: $533 · 2021: $740 · 2022: $602 · 2023: $620 · 2024: $618 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,551.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $804.27 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $321.31 | 2019-2023 | Xarelto |
| Amgen INC. | $269.06 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $261.97 | 2019-2023 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $248.70 | 2019-2025 | Verquvo, Belsomra |
| Astrazeneca Pharmaceuticals LP | $241.82 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Allergan, INC. | $215.26 | 2019-2020 | |
| Antares Pharma, INC. | $183.71 | 2022-2024 | Xyosted, Tlando, Nocdurna |
| Amarin Pharma, INC. | $136.36 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $133.37 | 2022-2025 | |
| Alkermes, INC. | $118.54 | 2021-2022 | |
| Glaxosmithkline, LLC. | $100.03 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $96.81 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.91 | 2020-2023 | Trintellix |
| Paratek Pharmaceuticals, INC. | $84.77 | 2025 | Nuzyra |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.73 | 2020-2025 | Jardiance, Trijardy Xr |
| Pfizer INC. | $83.60 | 2020-2021 | |
| Halozyme INC | $80.72 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.95 | 2019-2023 | Xifaxan, Trulance |
| Exact Sciences Corporation | $52.04 | 2023-2024 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $49.94 | 2023-2024 | Auvelity |
| Nestle Healthcare Nutrition INC. | $48.39 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.62 | 2025 | Caplyta |
| Urovant Sciences INC | $31.58 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $21.87 | 2021 | |
| Dexcom, INC. | $20.80 | 2024 | Dexcom G6 Transmitter |
| Supernus Pharmaceuticals, INC. | $19.96 | 2021 | Xyosted, Tlando |
| Organogenesis INC. | $19.07 | 2024 | |
| Sanofi-Aventis U.S. LLC | $18.16 | 2022 | |
| Biogen, INC. | $17.81 | 2020 | |
| Xeris Pharmaceuticals, INC. | $13.74 | 2021 | |
| Avanir Pharmaceuticals, INC. | $13.34 | 2019 | |
| Genentech USA, INC. | $13.20 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $12.98 | 2021 | |
| Lilly USA, LLC | $12.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.